Medicare to Begin Covering Obesity Drugs for Millions of Seniors Starting This Week
Medicare is launching its Bridge program to cover popular obesity drugs for millions of seniors with a $50 monthly copay, a landmark shift in policy. Despite the change, a recent survey found 82% of older Americans are unaware of the new benefit. The quiet rollout by both the government and drugmakers like Novo Nordisk and Eli Lilly may be a deliberate strategy to allow the healthcare system to prepare for a potential surge in demand from patients.
Medicare Bridge program launch
▪Starting July 1, 2026, Medicare's new Bridge demonstration program will cover obesity drugs for eligible beneficiaries for a $50 monthly copay.
▪The U.S. government has extended the Medicare Bridge program, which covers obesity drugs, through 2027.
Limited public awareness
▪The Obesity Care Advocacy Network survey was conducted in late March among more than 2,100 adults aged 65 and older.
▪Dr. Shauna Levy of the Tulane Bariatric and Weight Loss Center believes a lack of public information will delay patients from learning about the Bridge program.
▪A survey by the Obesity Care Advocacy Network found that 82% of Americans aged 65 and older are unaware that Medicare is about to cover obesity drugs.
Pharmaceutical company marketing strategy
▪In the first 9 months of 2025, Novo Nordisk spent nearly $500 million advertising its GLP-1 drugs, while Eli Lilly spent over $200 million.
▪Novo Nordisk and Eli Lilly have done limited advertising to the general public about the new Medicare coverage for their obesity drugs.
▪Jamey Millar of Novo Nordisk said the company believes patient awareness will come from providers and pharmacists rather than direct advertising.
Patient eligibility requirements
▪To qualify for the Bridge program, Medicare beneficiaries must be enrolled in a Part D prescription drug plan and obtain prior authorization from CMS.
▪Enrollment in the Bridge program is not automatic, and patients already receiving Medicare coverage for a GLP-1 drug for other conditions will not qualify.
Gradual rollout strategy
▪Some experts believe the limited public outreach is a deliberate strategy to allow physicians, pharmacies, and CMS to prepare for a potential surge in demand.
▪A Centers for Medicare & Medicaid Services (CMS) official stated the agency limited public outreach before the launch because beneficiaries act when a benefit is available.
Story comments
Loading comments…